PROVECTUS BIOPHARMACEUTICA-A PVCT

US Healthcare Pharmaceutical Preparations
$0.07
-1.4%
52w: $0.04 – $0.10

Latest 13F among current holders filed 1 month ago (May 15, 2026)

Price — last 12 months

research preview data
0.040.070.10
Jun 20, 2025 Jul 2, 2026
Institutional holders
6
+1 QoQ
13F value
$10K
+1.4% QoQ
Smart-money holders
1
signal tier ≥ 2
New smart buyers
0
Q1 2026

Institutional value by quarter

$33K
Q1 2024
$32K
Q2 2024
$22K
Q3 2024
$21K
Q4 2024
$23K
Q1 2025
$17K
Q2 2025
$20K
Q3 2025
$10K
Q4 2025
$10K
Q1 2026

Number of holders

6
Q1 2024
7
Q2 2024
7
Q3 2024
6
Q4 2024
7
Q1 2025
7
Q2 2025
7
Q3 2025
5
Q4 2025
6
Q1 2026

Who owns PVCT?

Q1 2026 filings
FundTypeSharesValue% of fundChange
HOME FEDERAL BANK OF TENNESSEE Wealth advisor100.0K$5K0.0%Held
Wealth Preservation Advisors, LLC Other52.6K$3K0.0%Held
ACADEMY CAPITAL MANAGEMENT ★3Fundamental concentrated20.0K$1K0.0%Held
Atlas Wealth LLC Other19.6K$9990.0%New
Financial Symmetry Inc Wealth advisor10.2K$5810.0%Held
HUNTINGTON NATIONAL BANK Diversified mechanical1$00.0%Held

Exits are not a bearish signal: our backtest shows stocks specialists exit keep outperforming for 3+ quarters — selling usually means profit-taking, not a forecast.